Literature DB >> 34240442

Wooden Chest syndrome: The atypical pharmacology of fentanyl overdose.

Joseph V Pergolizzi1,2,3, Lynn R Webster4, Eugene Vortsman5, Jo Ann LeQuang1, Robert B Raffa2,3,6,7.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: A large percentage of opioid overdose fatalities involve fentanyl or one of its legal or illegal analogs (F/FAs). Is there something about the pharmacology of these drugs that make them unusually dangerous in an overdose? COMMENT: Some of the reasons for the dangers of overdose of F/FAs is their high potency and low cost (that leads to wide distribution). But it is rarely asked if the basic pharmacology of F/FAs differ in some fundamental way from conventional opioids such as morphine and heroin. In addition to centrally mediated respiratory depression via opioid receptors, F/FAs cause rigidity in the key respiratory muscles of the chest, upper airway and diaphragm ("wooden chest syndrome," WCS) by a non-opioid mechanism. WHAT IS NEW AND
CONCLUSION: WCS is an atypical pharmacology of F/FAs. Because of its rapid onset and non-opioid mechanism, WCS makes F/FA overdose particularly dangerous.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  fentanyl; fentanyl analogs; opioid overdose; wooden chest syndrome

Mesh:

Substances:

Year:  2021        PMID: 34240442     DOI: 10.1111/jcpt.13484

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  2 in total

1.  Efficacy and Selectivity of Monovalent and Bivalent Vaccination Strategies to Protect against Exposure to Carfentanil, Fentanyl, and Their Mixtures in Rats.

Authors:  Bethany Crouse; Mariah M Wu; Valeria Gradinati; Andrew J Kassick; Daihyun Song; Rajwana Jahan; Saadyah Averick; Scott Runyon; Sandra D Comer; Marco Pravetoni
Journal:  ACS Pharmacol Transl Sci       Date:  2022-04-20

Review 2.  Treatment of opioid overdose: current approaches and recent advances.

Authors:  Stevie C Britch; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2022-04-07       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.